Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing

The University of Texas System (UT)

Status and phase: Completed; Phase 1

Conditions: Chronic Lung Disease of Prematurity; Bronchopulmonary Dysplasia; Bronchopulmonary Dysplasia Associated Pulmonary Hypertension; Pulmonary Hypertension; Premature Birth

Treatments: Dietary Supplement: Enteral L-citrulline

Study type: Interventional

Funder types: Other

Identifiers

NCT03649932

17-0194

Details and patient eligibility

About

Oral L-citrulline supplementation may prevent and/or decrease the severity of chronic lung disease associated with pulmonary hypertension in preterm infants. Since oral L-citrulline supplementation has never been studied in preterm infants before, the side effect profile and appropriate dosing are still unknown. In this pilot study, the investigators will determine the safety profile, efficacy and appropriate dosing of oral L-citrulline in preterm infants. In the future, information from this study will be utilized to conduct a randomized placebo-controlled trial to evaluate the role of L-citrulline supplementation in treating BPD_PH.

Full description

Bronchopulmonary dysplasia (BPD) is the most common chronic lung disease in preterm infants (PI). Preterm birth causes disruption in pulmonary vascular growth that leads to decreased vascular surface area that increases pulmonary vascular resistance (PVR). Increased PVR leads to altered vasoreactivity and structural remodeling with intimal hyperplasia and increased muscularization of the small pulmonary arteries. There is no definite treatment for BPD_PH.

Nitric Oxide: Nitric Oxide (NO) is a potent pulmonary vasodilator. Endothelial Nitric oxide synthase (eNOS) mediates production of NO from L-Arginine. L-citrulline is a precursor for L-arginine. L-Arginine is a precursor of nitric oxide (NO). In infants with BPD_PH, there are decreased levels of L-arginine & L-citrulline with decreased production of NO (measured by urinary nitrates & nitrites) leading to increased PVR. Several studies have shown the benefit of oral L-citrulline supplementation in increasing serum citrulline levels, increasing NO production and reducing pulmonary hypertension. Oral L-arginine was not effective in increasing NO production in previous studies and it was due to increased break down of oral L-arginine by intestinal arginases.

Source of L-arginine in preterm infants: Routinely, extremely premature infants receive nutrition as total parental nutrition (TPN i.e. infants get infusion of protein, fat and carbohydrate via central venous line) that contains L-arginine (approximately 1mg/1mL) to metabolize ammonia via urea cycle. PIs receive adequate amount of intra venous arginine from TPN. Routinely, PIs are started with small volumes of enteral feeds which are increased slowly overtime. TPN is slowly decreased as enteral feeds are increasing. As the TPN is going down, intra venous L-arginine intake also drops down and ultimately when the PI are off TPN, they don't get any IV supplemental L-arginine.

Why oral citrulline: Enteral feeds (formula as well as breast milk) is poor source of arginine. Once PIs are on full enteral feed, an enteral feed is the only source of arginine. Interestingly, 40% of enteral arginine gets metabolized by arginase enzyme present in intestine. We speculate that plasma levels of arginine drop once TPN is discontinued and infants are on full feeds. Oral L-arginine has poor bio-availability that is why oral L-arginine supplementation does not increase blood levels of arginine. Since oral citrulline has high bioavailability, the best way to increase serum arginine levels is by oral citrulline supplementation. Oral supplementation of L-citrulline in preterm infants once they are off TPN will likely to increase arginine levels and NO production.

Safety of oral citrulline: L-citrulline has been safely used for decades in patients with urea cycle defects. It has been used in pediatric patients with sickle cell disease and in infants undergoing cardiac surgery. No side effects were reported in these studies. In a study in newborn rats exposed to hyperoxia, L-citrulline caused a marked increase in arginase-2 expression in the lungs and this could have an impact on lung development and remodeling. However, this is only a theoretical risk.

Enrollment: 42 patients

Sex: All

Ages: Under 30 weeks old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Infants less than or equal to 30 weeks' gestational age born at UTMB, Galveston.
• Parents have provided informed consent/assent in a manner that is approved by the IRB

Exclusion criteria

• Known congenital or chromosomal anomalies.
• Congenital heart disease affecting cardio-respiratory system (other than PDA, PFO or ASD)
• Necrotizing enterocolitis, sepsis, or any condition requiring surgery prior to recruitment

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

42 participants in 3 patient groups

L-citrulline 100 mg/kg/day

Experimental group

Description:

50 mg/kg given two times a day (100 mg/kg/day) for total 7 days.

Treatment:

Dietary Supplement: Enteral L-citrulline

L-citrulline 200 mg/kg/day

Experimental group

Description:

100 mg/kg given two times a day (200 mg/kg/day) for total 7 days

Treatment:

Dietary Supplement: Enteral L-citrulline

L-citrulline 300 mg/kg/day

Experimental group

Description:

150 mg/kg given two times a day (300 mg/kg/day) for total 7 days.

Treatment:

Dietary Supplement: Enteral L-citrulline